dezocine

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: dezocine
• 英文别名: (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol；(1R,9S,15R)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol
• 化学式: C₁₆H₂₃NO
• 分子量: 245.365
• InChiKey: VTMVHDZWSFQSQP-APHBMKBZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 dezocine 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以298 mg的产率得到
  参考文献：
  名称：

  CN116478060

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
  申请人：NOVARTIS AG

  公开号：WO2006018284A1

  公开（公告）日：2006-02-23

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。
• Bioreponsive Polymers
  申请人：Laronde Frank

  公开号：US20100041771A1

  公开（公告）日：2010-02-18

  The invention features biodegradable polymers for the delivery of biologically active agents. The polymers include at least one biologically active agent covalently attached via a polyamide linker susceptible to selective hydrolysis by peptidase enzymes. Hydrolysis of the polyamide linker releases the biologically active agent in vivo.

  这项发明涉及生物活性剂的传递的可生物降解聚合物。这些聚合物包括至少一个生物活性剂，通过易受肽酶选择性水解的聚酰胺连接物共价连接。聚酰胺连接物的水解会在体内释放生物活性剂。
• Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
  申请人：MILLER Frederick H.

  公开号：US20100221321A1

  公开（公告）日：2010-09-02

  A method and apparatus for delivering a plurality of medicaments in a single delivery vehicle for the management of co-morbid diseases, illnesses and conditions. The present invention provides a novel delivery process for many medicaments. Medicaments may be encapsulated and stored separately within a larger capsule until the time of ingestion, consumption, or the like. Benefits of the present invention include maintaining separation of distinct ingredients within a single capsule and the capability to control the time release of multiple ingredients within the capsule.

  一种用于管理共病疾病、疾病和病状的多种药物在单一输送装置中输送的方法和装置。本发明提供了一种新颖的多种药物输送过程。药物可以被封装并分别存储在更大的胶囊中，直到摄入、消耗或类似的时间。本发明的好处包括在单个胶囊中保持不同成分的分离以及控制胶囊中多种成分的时间释放的能力。
• Methods and compositions for the delivery of biologically active agents
  申请人：Esfand Roseita

  公开号：US20070037891A1

  公开（公告）日：2007-02-15

  The invention features polymers noncovalently complexed with a biologically active agent. The polymer complexes include at least one shielding moiety covalently tethered to at least one complexing moiety, which is complexed with at least one biologically active agent.

  该发明涉及与生物活性剂非共价配合的聚合物。聚合物复合物包括至少一个与至少一个复合基团共价连接的屏蔽基团，该复合基团与至少一个生物活性剂复合。
• 1H-QUINAZOLINE-2,4-DIONES
  申请人：NOVARTIS AG

  公开号：US20130296332A1

  公开（公告）日：2013-11-07

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式(I)的1H-喹唑啉-2,4-二酮，其中R1和R2如规范所定义，它们的制备，它们作为药物的用途，以及含有它们的药物组合物。此外，还公开了制造公式(I)化合物的中间体和包含公式(I)化合物的组合物。